ORCID: https://orcid.org/0000-0002-2597-1992; Steward, Anna ORCID: https://orcid.org/0000-0002-8438-3760; Dewenter, Anna ORCID: https://orcid.org/0000-0002-5636-196X; Dehsarvi, Amir ORCID: https://orcid.org/0000-0001-7116-9741; Zhu, Zeyu ORCID: https://orcid.org/0000-0003-0970-4832; Roemer‐Cassiano, Sebastian N; Frontzkowski, Lukas ORCID: https://orcid.org/0000-0001-9321-956X; Hirsch, Fabian; Palleis, Carla ORCID: https://orcid.org/0000-0002-4331-8145; Höglinger, Günter U. ORCID: https://orcid.org/0000-0001-7587-6187; Brendel, Matthias ORCID: https://orcid.org/0000-0002-9247-2843 und Franzmeier, Nicolai ORCID: https://orcid.org/0000-0001-9736-2283
(2025):
A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease.
In: Alzheimer's & Dementia, Bd. 21, Nr. 10, e70783
[PDF, 7MB]
Abstract
INTRODUCTION
With anti-amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compared longitudinal changes in A/T/N biomarkers (amyloid-positron emission tomography [PET], tau-PET, plasma phosphorylated tau at threonine 217 [p-tau217], and magnetic resonance imaging) for tracking cognitive changes.
METHODS
We analyzed longitudinal biomarker and cognitive change rates from the Alzheimer's Disease Neuroimaging Initiative (N = 141) and Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) (N = 151), estimated using linear mixed models. Using linear models, we tested biomarker changes as predictors of cognitive changes, comparing predictive strengths across biomarkers using bootstrapping.
RESULTS
Tau-PET, plasma p-tau217, and cortical thickness changes accurately tracked change rates in Mini-Mental State Examination, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item version, Clinical Dementia Rating-Sum of Boxes, and Preclinial Alzheimer Cognitive Composite scores. In contrast, amyloid-PET change rates were not linked to cognitive changes.
DISCUSSION
Plasma p-tau217 offers a cost-effective AD-specific alternative to tau-PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid-PET lacks utility. Cortical thickness changes accurately track cognitive changes but may be confounded by pseudo-atrophy in anti-Aβ treatments.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy) |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| URN: | urn:nbn:de:bvb:19-epub-129550-1 |
| ISSN: | 1552-5260 |
| Bemerkung: | for the Alzheimer's Disease Neuroimaging Initiative (ADNI) |
| Sprache: | Englisch |
| Dokumenten ID: | 129550 |
| Datum der Veröffentlichung auf Open Access LMU: | 18. Nov. 2025 12:54 |
| Letzte Änderungen: | 18. Nov. 2025 12:54 |
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |
- Dokument bearbeiten
